The KCTD3 Knouckout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of A-549 human lung epithelial carcinoma cells harboring disruption of the KCTD3 gene. This heterogeneous knockout pool provides a loss-of-function model for investigating KCTD3-mediated ubiquitination and signaling without clonal selection constraints. The ablation of KCTD3 protein expression is broadly distributed across the population, enabling bulk functional assays such as proteomic profiling and pooled genetic screens. Retaining the parental A-549 genetic background, including the KRAS G12S driver mutation, these cells offer a physiologically relevant system to study KCTD3-dependent processes in a lung adenocarcinoma context.
A-549 cells were derived from a lung carcinoma of a 58-year-old male and display type II alveolar epithelial-like features. They harbor an oncogenic KRAS G12S mutation that constitutively activates MAPK signaling, making them a prominent model for non-small-cell lung cancer research. The adherent epithelial phenotype and well-characterized transcriptome facilitate integration with existing omics datasets. This KRAS-mutant background allows dissection of how KCTD3 loss may intersect with proliferative and survival pathways, particularly given the emerging roles of ubiquitin ligase adaptors in cancer.
KCTD3 acts as a substrate-specific adaptor for cullin3-RING E3 ubiquitin ligase (CRL3) complexes, directly binding CUL3 and RBX1 to recruit target proteins for ubiquitination and proteasomal degradation. Its primary substrates include GABA-B receptor subunits GABBR1 and GABBR2, as well as potassium channels KCNQ2 and KCNQ3. By regulating the surface expression and stability of these receptors, KCTD3 modulates GABAergic signaling and neuronal excitability. This adaptor function positions KCTD3 at a critical interface between the ubiquitin-proteasome system and ion channel trafficking, with implications for synaptic transmission and action potential dynamics.
In the A-549 lung adenocarcinoma context, the KCTD3 knockout model enables investigation of ubiquitin-mediated processes in cancer cell biology. Although KCTD3 is primarily associated with neurodevelopmental disorders and epilepsy, its potential role in tumorigenesis??possibly through altered protein turnover or ion channel regulation??can be systematically explored. The KRAS-mutant background may reveal dependencies on KCTD3 for maintaining malignant phenotypes or drug resistance. Additionally, A-549 cells endogenously express relevant ion channels, allowing electrophysiological studies of how KCTD3 loss affects potassium currents in epithelial carcinoma cells, thus extending the model??s utility from neuroscience to oncology.
Researchers can apply these knockout cells in diverse assays: co-immunoprecipitation to probe CUL3 complex integrity, Western blotting for ubiquitination profiling, immunofluorescence to localize GABA-B receptors or KCNQ channels, and patch-clamp recordings to assess potassium channel function. Flow cytometry enables quantification of cell surface receptor levels, while RT-qPCR validates downstream transcriptional effects. These applications support mechanistic dissection of CRL3-dependent proteostasis, high-content phenotypic screens, and target validation studies. For additional details or ordering information, contact Ascent Research.
